The effects of major depressive disorder (MDD) on neurocognitive function remain poorly understood. Results from published studies vary widely in terms of methodological factors, and very little is known about the effects of depression severity and other clinical characteristics on neurocognitive function. The purpose of this review was to synthesize prior research findings regarding neurocognitive functioning in patients with MDD and varying levels of depression severity and to provide recommendations for future directions. Overall, this review suggests that MDD has been inconsistently associated with neurocognitive functioning and there is limited understanding regarding the relationship between depression severity and neurocognitive sequelae. There was much heterogeneity on depression severity-related factors across studies assessing neurocognitive function in MDD, as well as substantial variability in the consideration of depression severity among studies, which suggests a need to further explore this important issue.
It has long been noted that major depressive disorder (MDD) can negatively affect neurocognitive function (Schatzberg, 2002; Shenal, Harrison, & Demaree, 2003; Zakzanis, Leach, & Kaplan, 1999) . The majority of studies have focused on MDD collectively in relation to cognitive functioning, and in addition to sampling differences, many do not comment on unique or additional depression characteristics such as symptom severity at the time of assessment. Of clinical relevance, some patients with MDD show cognitive difficulties whereas others do not. The emphasis on MDD collectively has left a gap in the research, and in turn clinical practice, concerning the relationship between magnitude of depression severity and neurocognitive function (Zakzanis et al., 1999) . The result of this gap is significant, as cognitive impairments associated with MDD can significantly reduce function, impair quality of life, and contribute to disability (Jaeger, Berns, Uzelac, & Davis-Conway, 2006; Naismith, Longley, Scott, & Hickie, 2007) .
Major depression has been negatively associated with the neuropsychological domains of executive function (Harvey et al., 2004) , attention and concentration (Kampf-Sherf et al., 2004) , memory (Fossati, Amar, Raoux, Ergis, & Allilaire, 1999) , and processing speed (Nebes et al., 2000) . In a meta-analysis of 22 studies, Zakzanis and colleagues (1999) showed that declarative or episodic memory (mean effect size, Cohen's d ϭ 0.73) and attention (mean effect size ϭ 0.59) were the cognitive domains that tended to be most affected by depression. Moreover, neurophysiological studies have implicated the role of the prefrontal cortex and the hippocampus in MDD (Elliott, Rubinsztein, Sahakian, & Dolan, 2002; Schatzberg, 2002) . However, there has been considerable variability in methodologies across studies thereby contributing to some of the inconsistencies in the neurocognitive associated effects of depression.
The purpose of this review was to synthesize prior research findings regarding associations between depression severity and neurocognitive functioning in MDD, and further to provide recommendations for future directions. To accomplish a systematic literature review (Wright, Brand, Dunn, & Spindler, 2007) , we searched the PsychInfo and Medline databases (English language literature, 1980 (English language literature, to 2008 OvidSP, Ovid Technologies, Inc.) with the following terms (e.g., OvidSP subject headings): major depressive disorder and neuropsychology. To control for duplicate information and redundancy, the results were imported and managed with Endnote (Version ϫ 2 for Mac, The Thomson Corp., New York, NY). When we encountered studies with overlapping participant samples, the studies with the smaller sample sizes were excluded from consideration. A total of 35 studies (see Table 1 ) that focused on depression severity were included in this review. These studies were published between 1991 and 2007, from multiple countries of origin (Australia, Belgium, Canada, Denmark, France, Germany, Israel, New Zealand, Norway, Sweden, United Kingdom, United States), and the sample sizes ranged from 40 to 420 (M ϭ 113.4, SD ϭ 85.2).
MDD
Depression has been found to be the fourth leading cause of disability worldwide (Moussavi et al., 2007) , and those with depression have a higher mortality rate relative to those persons not (text continues on page 25) depressed (Cuijpers & Smit, 2002) . The lifetime prevalence of MDD ranges between 5% and 20% (Hamet & Tremblay, 2005; Kessler et al., 2003) . The annual incidence of MDD has been found to be three to five adults per 1,000 (J. M. Murphy, Laird, Monson, Sobol, & Leighton, 2000) and it has been estimated that 5% to 25% of the population will experience depression at some point in their lifetime . Women are consistently diagnosed with MDD more frequently than men at a ratio of 2:1 (Kessler, 2003; Marcus et al., 2005) , and younger cohorts (50 years and younger) have been found to have higher rates of depression relative to older (51 years and older) cohorts (Husain et al., 2005) .
Defining Depression Severity
Severity of depression, and its potential effects on cognitive function, should be considered both with respect to the level of symptom severity at the time of neuropsychological testing (i.e., state of depressive symptomatology), and with respect to course of illness (i.e., number and duration of depressive episodes, duration of illness, treatment resistance). These different aspects of severity may influence both neuropsychological performance and the potential resolution of cognitive impairments with treatment.
Evaluation of depressive symptoms at a particular time point is typically done with symptom rating scales, such as the Hamilton Rating Scale for Depression (HAM-D; Hamilton, 1960) , or the Inventory of Depressive Symptomatology (IDS; Rush, Gullion, Basco, Jarrett, & Trivedi, 1996) . Different total scores correspond to various levels of severity. For example, scores ranging between 0 and 11 on the 30-item IDS and 0 to 7 on the 17-item HAM-D represent no depression (or remission), whereas 47 or greater on the IDS and 26 or greater on the HAM-D represent very severe depression (http://www.ids-qids.org). These symptom severity scores are often correlated with neuropsychological test performance to evaluate the relationship between symptom severity and cognitive function.
The presence or absence of psychotic features is also evaluated when examining depression severity at the symptom level (Fennig, Craig, Lavelle, Kovasznay, & Bromet, 1994) . Psychosis, per the Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR; American Psychiatric Association, 2000), is an indicator of depression severity rather than a subtype of depression, and is qualified as either mood congruent (e.g., content is consistent with depressive theme) or mood incongruent. Research has suggested that persons diagnosed with psychotic depression are older, have worse premorbid functioning and longer depressive episode duration, and are more prone to future psychotic depressive episodes (Bromet et al., 1992; Craig, Grossman, Bromet, Fochtmann, & Carlson, 2007; Naz et al., 2007) .
In addition, aspects about individuals' course of illness-such as number of depressive episodes and duration of episodes, as well as age at onset of depression-may impact cognitive performance. Treatment resistance is also a relevant consideration, as it contributes to longer episodes, as well as the likelihood for exposure to more types of psychotropic medications and combinations of psychotropic medications for a longer period of time, which is negatively associated with cognitive function (Gibel & Ritsner, 2008; Neumann et al., 2002 ).
Of note, many studies included both inpatients and outpatients, which contributes to a wide range of severity in study samples being assessed. These patient samples (inpatients or outpatients) are likely to differ on all aspects of severity discussed above. In addition, they are likely to differ with respect to current treatments, as well as past treatment history, both of which may be associated with cognitive performance. Therefore, it is important to consider the distribution of such patients in studies examining cognitive impairment in depression.
Recurrent and Single Episode Depression
For those persons diagnosed with MDD, between 50% and 75% experience more than one depressive episode (Gold & Chrousos, 2002; Harkness, Monroe, Simons, & Thase, 1999; Kennedy & Paykel, 2004) . Typically, the subsequent depressive episode occurs within 6 months after recovering from the first episode, with recurrence increasing proportionally to the number of subsequent episodes (Angst, 1999) . Illustrating the high recurrence rate, a longitudinal study following 69 participants with MDD over a 20-year time period showed that over 92% recovered on average by 12 months (median recovery time was 7 months) and 67% of those who recovered later had a recurrence of depression (Kennedy, Abbott, & Paykel, 2003) .
Recurrent depression has been suggested to be more severe and disabling than single episode depression (Paradis, Reinherz, Giaconia, & Fitzmaurice, 2006) . Those with chronic, recurrent depression have been shown to have more Axis I (i.e., anxiety, substance abuse), Axis II (i.e., personality disorder), and Axis III (i.e., somatic complaints, somatic diseases) comorbidities (Katon, 2003; Vuorilehto, Melartin, & Isometsa, 2005) . Moreover, recurrent depression has been associated with increased negative perceptions of social stimuli (i.e., vocal expressions, facial expressions) and self (Bos et al., 2005) , as well as poor marital and interpersonal relationships and poor employment functioning (Elinson, Houck, Marcus, & Pincus, 2004; Judd et al., 2000; Kennedy & Paykel, 2004; Kessler, 1997; Wilhelm, Parker, Dewhurst-Savellis, & Asghari, 1999) , which suggests recurrent depression, relative to single episode, may be more deleterious. However, in The Netherlands Mental Health Survey and Incidence Study (Kruijshaar, Hoeymans, Bijl, Spijker, & Essink-Bot, 2003) , the severity of the depressive episode was found to be more related to increasing levels of disability as opposed to the number of depressive episodes. Thus, there is conflicting evidence as to whether severity of the depressive episode or the number of depressive episodes may contribute more strongly to the level of functional impairment.
Physiological correlates of recurrent MDD have included increased cortisol (Bos et al., 2005) , glucocorticoids (Lampe et al., 2003) , and decreased hippocampal volume (Neumeister et al., 2005) . The reduction in the hippocampus was found to be most prominent in the posterior region that has specific implications in spatial learning and memory (Porter, Gallagher, Thompson, & Young, 2003) . A relationship has been shown to exist between recurrent MDD and increased cortisol and decreased hippocampal volume, as well as reduced cerebral gray matter volume (i.e., decrease in neuron and glial cell density and size; Cotter, Mackay, Landau, Kerwin, & Everall, 2001; Rajkowska, 2000) .
There is conflicting information regarding the association between cognitive function and recurrent depression. A major de-pressive episode (MDE) can be conceptualized as a traumatic event that potentially could harm the brain and negatively impact cognitive functioning, with more MDEs causing more harm than one (Altshuler, 1993; Fossati, Coyette, Ergis, & Allilaire, 2002; Rapp et al., 2005) . Various researchers (Burt, Prudic, Peyser, Clark, & Sackeim, 2000; Grant, Thase, & Sweeney, 2001) have speculated that there is a cumulative, neurotoxic effect of MDEs on brain physiology, which may be associated with neuropsychological dysfunction. For example, the number of depressive episodes has been associated with a decrease in cognitive performance (Kessing, 1998) on the Cambridge Cognitive Examination total score (CAMCOG; Huppert, Brayne, Gill, Paykel, & Beardsall, 1995) , a computerized neuropsychological screening tool. Also, those with recurrent depression were found to be more impaired on the Wisconsin Card Sorting Test (Heaton et al., 1993) , a measure of problem solving, the Paced Auditory Serial Addition Test (Gronwall, 1977) , a measure of attention and working memory, and the Stroop test (Stroop, 1935) , a measure of inhibition and executive function, compared to control participants (Stordal et al., 2004) .
In contrast, research by Grant et al. (2001) showed no relationship between the number of MDEs and performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB; Fray, Robbins, & Sahakian, 1996) , a computerized screening battery that assesses memory, attention, and executive function. The conflicting information regarding the association between the number of MDEs and neurocognitive performance could be attributable to multiple factors including methodological (i.e., different neurocognitive instruments) or sample (i.e., sociodemographic or clinical characteristics) related differences among studies. Also, although the number of MDEs may have a cumulative effect on cognitive function, several investigators suggested that after the depressive episode remits, cognitive functioning often returns to normal. During the euthymic state, it is believed that the brain heals itself, in turn improving and returning cognitive functioning back to normal (Hammar, Lund, & Hugdahl, 2003; Neu et al., 2005) . However, other recent studies have suggested that at least certain aspects of neurocognitive dysfunction (e.g., effortful attention) are resistant to antidepressant treatment (e.g., selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitor) and remain even when the depressive episode has remitted (Gualtieri, Johnson, & Benedict, 2006; Paelecke-Habermann, Pohl, & Leblow, 2005) .
Neurophysiological and Neurobiological Correlates of MDD
In general, MDD has often been associated with neurophysiological changes (Liotti & Mayberg, 2001) . Studies using positron emission tomography (PET) have shown decreased regional cerebral blood flow (rCBF) in areas that have been implicated in affective disorders including the medial prefrontal cortex, anterior cingulate, and the orbital frontal cortex (Dolan, Bench, Brown, Scott, & Frackowiak, 1994; Elderkin-Thompson, Boone, Hwang, & Kumar, 2004) . Moreover, in a study of 10 depressed patients assessing mood-congruent processing biases using functional magnetic resonance imaging (fMRI), it was found that abnormal responses were associated with the medial and orbital prefrontal cortices (Elliott et al., 2002) . Other neuroimaging studies have shown abnormal functioning in frontal and limbic connections using fMRI (Krishnan, Hays, & Blazer, 1997) , or increased glucose metabolism in the caudate nucleus (Drevets, 2000) , and the limbic regions using PET. In the study by Krishan et al. (1997) , late-life depression was hypothesized to be related to vascular lesions in the frontal and limbic connections that may dysregulate norepinephrine and serotonin circuitry. This concept of "vascular depression" was proposed by Alexopoulos et al. (1997) , based on their finding of associations between depression, vascular lesions, and vascular risk factors. Additional research has found that cerebral emboli were greatly associated with depressive symptoms, even after adjusting for demographic factors in a cohort of older patients with vascular dementia (Purandare et al., 2006) . Though no investigations have examined the association between vascular lesions and depression severity, this line of investigation could provide useful information particularly with regard to addressing the effects of the number of lesions and depression severity, and then followed by treatment options (for a comprehensive review, see Blazer, 2009 ).
Neurobiologically, serotonergic and hypothalamic pituitary axis (HPA) dysfunction has been suggested to impact neurocognitive functioning in those persons with depression (McAllister-Williams, Ferrier, & Young, 1998) . As identified in PET studies, the serotonergic system is abnormal in depressed patients as there are fewer serotonin receptors (i.e., 5-HT 1a ) and the serotonin transportation mechanism (5-HTT) is inefficient (Drevets, Frank, & Price, 1999) . The above information helps to support the association between MDD, neuroanatomical regions, and neuropsychological processes; however, the nature of that relationship and the potential impact of other factors is unclear.
Pseudodementia
Depression, when very severe, has been reported to cause such significant cognitive impairments in some individuals such that persons may be described as having pseudodementia, which is defined as reversible impairment of memory secondary to depression (Salzman & Guitfreund, 1986) . Although it may be difficult in rare cases to differentiate dementia from pseudodementia, in true dementia, cognitive decline progresses over time, whereas in pseudodementia, the cognitive loss follows after the onset of MDD (McBride & Abeles, 2000; Reynolds & Hoch, 1987; Reynolds et al., 1988) . Disorders that cause dementia such as Alzheimer's disease also tend to have characteristic neuropsychological profiles that help distinguish dementia from depression (Kasahara et al., 2006; Naugle, Cullum, & Bigler, 1998) . There has been considerable debate as to whether depression serves as a prodromal stage (Broe et al., 1990) or a risk factor for dementia (Barnes, Alexopoulos, Lopez, Williamson, & Yaffe, 2006; Devanand et al., 1996; Geda et al., 2006) . For example, in a large cohort (N ϭ 1,070) of community living people over the age of 65, pseudomentia showed a 0.6% prevalence rate, and of the six persons diagnosed with pseudodementia, only two developed dementia (Copeland et al., 1992) . However, in a separate large cohort (N ϭ 1,070) of persons age 60 years or older who were part of a dementia registry, baseline depressed mood was found to increase the risk of incident dementia (Devanand et al., 1996) . Also, Saez-Fonseca, Lee, and Walker (2007) found a relative risk of 3.929, 95% CI [1. 985, 7.775] , for the development of dementia in patients with depression and pseudodementia on a 5-or 7-year follow-up examination. Further, a recent study suggested that patients with late-life depression, even after successful antidepressant treatment, were more likely to be diagnosed with mild cognitive impairment (nonamnestic or amnestic subtype) or dementia, relative to a matched control group (Bhalla et al., 2009) . Thus, there is a complex association between depression and dementia (for a comprehensive review of the relationship between depression, pseudodementia, and dementia, see Butters et al., 2008) .
Neurocognitive Studies of MDD
Cognitive dysfunction related to MDD (see Table 1 for details of the studies discussed in this section) has been reported in some, but not all studies (Gorlyn et al., 2006; F. C. Murphy, Michael, Robbins, & Sahakian, 2003; Shenal et al., 2003) that examined varying degrees of depression severity (Landro, Stiles, & Sletvold, 2001) . In a study comparing 22 patients with nonpsychotic MDD to 30 healthy normal participants, Landro and colleagues (2001) found that those with MDD performed significantly worse in the domains of attention, working memory, verbal long-term memory, and verbal fluency. The depressed group scored more than 1.5 standard deviations lower in attention and working memory, 1.0 standard deviation lower in verbal long-term memory, and 0.5 standard deviations lower in verbal fluency. This is consistent with other findings indicating impairment in verbal fluency and cognitive flexibility (Beblo, Baumann, Bogerts, Wallesch, & Herrman, 1999; Leuchter et al., 2004) . For example, Beblo et al. (1999) found that 41 depressed patients, compared to a control group, performed worse (i.e., 1 standard deviation) on verbal fluency (Controlled Oral Word Association Test; Benton & Hamsher, 1983) and design fluency. Another study comparing patients with bipolar disorder or MD, and controls found the MDD group scored lower on a measure of nonverbal memory from the CANTAB battery (i.e., Match to Sample Task) relative to the control group, but the difference was minimal (Sweeney, Kmiec, & Kupfer, 2000) . Clinically, the relationship between MDD and global cognitive function may be modulated by depression severity. For example, one report noted that patients who required hospitalization for depression were found to have greater cognitive difficulties (Rohling, Green, Allen, & Iverson, 2002) . Even during euthymic and remission phases, the effects of depression severity may linger, influencing cognitive effectiveness. It has been postulated that due to the negative effects of the MDE, the brain, during the euthymic phase, is in a period of healing and may not function at its normal level (Kessing, 1998; Paradiso, Lamberty, Garvey, & Robinson, 1997) . However, Hammar et al. (2003) found in a cohort of 21 patients (18 hospitalized) with MDD that cognitive functioning returned to normal during remission. Depression severity may particularly impact aspects of memory. In research comparing 26 patients with MDD, 28 with minor depression, and 38 healthy controls, those with MDD were significantly more impaired on tests of verbal recall and set maintenance relative to the other groups. Those with minor depression were found to be mildly impaired on a measure of executive functioning (ElderkinThompson et al., 2003) , relative to healthy controls. Minor depression, as defined in the DSM-IV-TR (American Psychiatric Association, 2000) , is similar to MDD, except it consists of having only two to five depressive symptoms (one symptom must be either sad mood or anhedonia) for a minimum of 2 weeks. In the above study by Elderkin-Thompson et al. (2003) , working memory was assessed with the Digit Span subtest of the revised Wechsler Memory Scale (Wechsler, 1987) and executive functioning was assessed with a modified version of the Wisconsin Card Sorting Test. We found it interesting that other research has suggested that those with minor depression perform as well as controls on cognitive measures (Airaksinen, Larsson, Lundberg, & Forsell, 2004) .
Even though much of the above information suggests that MDD is negatively associated with cognitive functioning, some research has disagreed with that relationship (Austin, Mitchell, & Goodwin, 2001 ). Particularly in young adult patients with mild to moderate depression, cognitive compromise seems to be rare. For example, Wang et al. (2006) Beck, 1978) and healthy young adult control (N ϭ 36) cohorts. Gorlyn et al. (2006) examined performance on the Wechsler Adult Intelligence Scale (3rd ed., WAIS-III; Wechsler, 1997) in 121 severely depressed patients (based on DSM-IV criteria and the HAM-D) and 41 healthy controls. The depressed group performed worse on the performance IQ subtests, particularly those that were timed (e.g., Coding, Symbol Search), which also resulted in low scores on the processing speed index. In a longitudinal study (Cysique et al., 2007) assessing the impact of depression on cognitive functioning in a cohort of HIV positive men (N ϭ 227), no relationship was found between mild trait depression and objective neuropsychological measures, although a relationship was found between trait depression and subjective cognitive complaints. In the Cysique et al. (2007) study, neuropsychological performance was analyzed using normative adjusted T scores from the revised version of the Wechsler Adult Intelligence Scale (WAIS-R; Wechsler, 1981) and the Halstead-Reitan Battery (Heaton et al., 1991) . Moreover, in a study of 30 patients with MDD, executive function was found to improve after remission was achieved (Biringer et al., 2005) . Further research may help elucidate the relationship between depression severity and neurocognitive functioning as well as discern if normalization of function is time dependent postremission.
Attention and Memory
Both automatic and effortful attention can be negatively affected by MDD. In a study (Farrin, Hull, Unwin, Wykes, & David, 2003) of 102 men with MDD compared to 59 controls, the depressed group performed significantly worse on the Sustained Attention to Response Task (SART; Robertson, Manly, & Andrade, 1997) , a computer-administered test of visual attention. Also, impairment in divided attention, defined as difficulty in attending to both visual and auditory stimuli, was found to be predictive of the outcome of the depressive course in one study (Majer et al., 2004) . In the study by Majer et al. (2004) , the analyses controlled for age, gender, years of education, depression severity (as rated on the HAM-D), duration of illness, duration of hospitalization, type of antidepres-sant (activating or sedating), and other psychotropic medications (neuroleptic, mood stabilizer, tranquilizer).
Depression may also negatively impact different types of memory, including explicit, implicit, short term, long term, and working memory (Nitschke, Heller, Etienne, & Miller, 2004; Wang et al., 2006) . Performance on verbal memory tasks may result from poor frontal-temporal lobe functioning, preoccupation with negative thoughts, or decreased processing speed (Nebes et al., 2000) . In a study examining the relationship of the BDI (Beck, 1978) to different versions of the California Verbal Learning Test (CVLT; e.g., adult, child; Delis, Kramer, Kaplan, & Ober, 1987; Delis, Kramer, Kaplan, & Ober, 1994) , once adjusted for age, gender, and intelligence, depression accounted for only 2% of the variance in the CVLT score (O'Jile, Schrimsher, & O'Bryant, 2005) . Contrary to the above, persons with MDD have been found to score between 0.5 and 1 standard deviation (corrected for age, education, and gender) below the normative population on the CVLT List A total Trials 1 to 5 (Otto et al., 1994) . Behaviorally, MDD may also decrease individuals' abilities to carry out instrumental activities of daily living, which may affect patients' abilities to comply with cognitive testing Thus, there is an indication that those with MDD may not perform as well as those without MDD on measures of attention and/or memory.
Executive Functioning
Executive functioning (EF) has been defined as "the ability to maintain an appropriate problem-solving set for attainment of a future goal" (Welsch & Pennington, 1988, p. 201) . Expanding this definition, Welsch, Pennington, and Groisser (1991) added that EF includes the abilities of planning, performing organized searches, and controlling impulses.
EF can be negatively affected by depression as it has been shown to decrease initiation and problem solving (Elderkin-Thompson, Mintz, Haroon, Lavretsky, & Kumar, 2006; Harvey et al., 2004; Kiosses, Klimstra, Murphy, & Alexopoulos, 2001 ), affect planning (Rogers et al., 2004) , impair verbal fluency (Henry & Crawford, 2005) , and impede cognitive flexibility (Baudic, Tzortzis, Barba, & Traykov, 2004; Butters et al., 2004) . Although there is no consensus on the mechanisms of action, it is believed that depression is associated with frontal cortical impairment, which in turn leads to executive dysfunction because EF is mainly governed by the frontal cortices (Alvarez & Emory, 2006; Bravers et al., 1997; Carpenter, Just, & Reichle, 2000; Dolan et al., 1994; Kaiser et al., 2003) .
Research has indicated that depression severity may play a role in the degree of executive impairment (Taylor, Wagner, & Steffens, 2002) . Although the Taylor et al. (2002) study included patients who were diagnosed with MCI at baseline, in a small cohort (N ϭ 13) study, depression severity, as measured by the HAM-D (Hamilton, 1960) was found to be an independent predictor of total errors, perseverative responses, and failure to maintain set on the WCST (Martin, Oren, & Boon, 1991) . Contrary to this finding, Harvey and colleagues (2004) found no relationship between depression severity and the WCST in 22 depressed patients. Also, in one study, those with MDD were found to perform similarly to those with schizophrenia on the California Card Sorting Test (Delis, Squire, Bihrle, & Massman, 1992) . Both groups were found to be impaired in generating spontaneous sorts and they were unable to identify some of the sorting principles in the structured sort. The variable findings between the studies suggest that the relationship between EF and depression severity may be moderated by the EF measure used.
Influence of Medications and Comorbid Illness on Cognitive Function in MDD
It is important to consider not only the positive influence that antidepressant medication may have on cognitive function in depression, but also the potential adverse effects of pharmacotherapy. Here again, the impact of chronicity of depression is important because there is some evidence to suggest that long term and/or repeated exposure to some antidepressant medications may adversely affect cognitive function. For example, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) may worsen some cognitive processes such as reaction time and information processing speed, possibly due to the anticholinergic effects of these medications, whereas it has been noted that Selective Serotonin Reuptake Inhibitor (SSRI) may hold some benefit for cognitive function, particularly in older adults (Brooks & Hoblyn, 2007) . Similarly, medications for specific symptoms of depression, such as hypnotics used for insomnia, may independently impair cognitive function.
A related concern is the impact of comorbid diseases and depression. Depression is highly comorbid with many other chronic illnesses that can exert independent adverse effects on cognitive function. Increased age can be a contributing concern because the likelihood of comorbidity increases, as does the likelihood of polypharmacy, which may introduce additional adverse pharmacological effects on cognitive function. Psychiatric comorbidities such as substance abuse and anxiety are important to consider in depressed patients because of their independent potential effects on cognition. For example, substance abuse has been associated with both neurophysiological changes in frontostriatal brain regions, as well as objective cognitive impairments (Bechara & Martin, 2004; Lamers, Bechara, Rizzo, & Ramaekers, 2006; Robbins, Ersche, & Everitt, 2008; Salo, Ursu, Buonocore, Leamon, & Carter, 2009 ). Furthermore, treatments for substance use disorders, such as methadone and nicotine replacement therapies have also been associated with impaired cognitive function in some studies (Soyka et al., 2008; Spiga, Lintas, & Diana, 2008) . Similarly, anxiety, also known to be highly comorbid with depression, can affect cognitive processing in some cases, and is often treated with benzodiazepines, which have known negative effects on cognitive function (Buffett-Jerrott & Stewart, 2002) . In these cases, both the disease state and its treatment may contribute to cognitive impairments.
Many other general medical chronic diseases, such as diabetes and vascular illness, are highly comorbid with depression and can also independently impact cognitive function. Diabetes has been associated with some cognitive impairments (Awad, Gagnon, & Messier, 2004; Cukierman-Yaffe et al., 2009) , and these deficits may worsen with increasing age and/or the presence of vascular disease or depressive symptomatology (Awad et al., 2004) . Vascular illness is another example of a general medical condition that is highly comorbid with depression and associated with independent adverse effects on cognitive function (Roman et al., 2004; Sachdev et al., 2004; Waldstein et al., 2003) . The potential cumulative and additive cognitive impairments arising from comorbid psychiatric and medical condi-tions, as well as their treatments, must be considered when evaluating cognitive function in depression.
Summary of Findings
Depression is a significant clinical disease with varying levels of severity, each associated with degrees of impairment in the areas of social, functional, and interpersonal abilities. However, depression has been inconsistently associated with neurocognitive functioning (Gualtieri et al., 2006) and there is limited understanding regarding the relationship between depression severity and neurocognitive sequelae. Although research has shown detrimental effects in the domains of attention, learning and memory, and EF related to depression, there is disagreement as to the mediators of neurocognitive impairment, and for that matter, the mechanisms underlying the neurocognitive impairment. Several aspects of depression severity have been associated with more pronounced cognitive impairment, such as increased symptom severity at the time of neuropsychological testing. The presence of depression with psychosis may negatively impact neuropsychological domains such as EF, verbal and visual memory, and psychomotor skills to a greater extent relative to depression without psychotic features (Reichenberg et al., 2008) . In addition, recurrent depression has been associated with worse cognitive performance compared to single-episode depression (Kessing, 1998) , and longer depressive episodes have been associated with greater impairments on some aspects of executive function compared to shorter episodes (Grant et al., 2001) . Age of onset of depression (Driscoll et al., 2005 ) is a more complicated factor, with some evidence suggesting that an early onset depression (i.e., onset before age 55) is associated with poorer cognitive function (Majer et al., 2004) , although other evidence suggests that late-onset depression (i.e., onset at age Ն 55) is associated with poorer cognitive function (Elderkin-Thompson et al., 2006; Rapp et al., 2005) . However, many studies have found no relationship between course of illness factors and cognitive performance in depression (Biringer et al., 2005; Naismith et al., 2003; Porter et al., 2003) , and still more have not included assessments of such a relationship. It is clear that there is much heterogeneity on severity-related factors (i.e., level of symptom severity, course of illness characteristics) within samples assessing cognitive function in MDD, as well as substantial variability in the consideration of severity among studies, resulting in the need to further explore this important issue.
Future Directions
Individual studies examining cognitive deficits associated with MDD tend to not provide consistent information regarding depression severity (Zakzanis et al., 1999) , which has limited the understanding of the relationship between depression and neurocognitive function (Naismith et al., 2003) . This may be attributed to many factors such as limitations in quantifying the level of depression severity and deciding how to measure depressive symptoms (Gullion & Rush, 1998) . Although there is limited information regarding the cognitive effects associated with depression severity, this paucity in research demonstrates the importance of conducting further research in the relationship between cognitive functioning and intradomain specific depressive factors (Ebmeier, Donaghey, & Steele, 2006) . Although depression can negatively impact cognitive functioning in some cases (Shenal et al., 2003) , it is important to understand what specifically about MDD is affecting cognitive abilities. Furthermore, the factors associated with cognitive dysfunction in depression are not well understood. There is considerable variability and not all persons with MDD show reduced cognitive performance, although estimates of dysfunction have been found to range from mild to severe in the depressive population (Elliott, 1998; Veiel, 1997) . For example, is the variability in cognitive performance related to the number of depressive episodes, the severity of the major depressive episode, or the MDD subtype (i.e., melancholic, atypical)? Also, factors such as length of the depressive episode, onset of the depressive episode, and individual factors such as age, education, cognitive reserve, or genetic predisposition to depression, could play a role in the development of cognitive impairment secondary to depression.
Prior research has helped increase the understanding of the complex relationship between cognitive function and MDD; however, this understanding has been limited by small sample sizes, limited sociodemographic information (e.g., socioeconomic status, parental education), limited neurocognitive evaluations, and the use of either selfreport or clinician-rated depressive instruments as opposed to both. To Table 2 Recommendations for Future Study Directions address these limitations, future investigations (see Table 2 ) may benefit from better characterizing the sociodemographic and clinical characteristics of the sample to account for potential moderating factors (De Santi et al., 2008; Manly, 2008; Manly & Echemendia, 2007; Marcopulos & McLain, 2003; Salthouse, 2007) . Regarding depression severity, this could be enhanced by utilizing both self-report and clinician-rated depressive symptom severity instruments to help clarify the relationship between objective and subjective ratings on cognitive abilities. Also, the use of a standard neuropsychological battery that measures multiple-cognitive functions and includes demographic adjusted data would help to minimize age and education confounds. Given the limitations in prior studies and newer available methods, further research is needed to help clarify the relationship between major depressive disorder and cognitive functioning.
